NanoViricides Files Application for Rare Pediatric Disease Drug Designation for NV-387

NanoViricides, Inc., a publicly traded company, has submitted an application for the "Rare Pediatric Disease Drug" Designation (RPDD) for NV-387, intended to treat measles, with the US FDA's Office of Orphan Products Development. This comes after their application for Orphan Drug Designation in February 2026. Approval would make them eligible for a Priority Review Voucher (PRV), valued around $160 million.

This designation could bolster the economic case for NV-387, especially as measles cases surge, with 1,661 cases reported across 33 US states in 2026. Measles remains prevalent in unvaccinated populations despite vaccination efforts, highlighting the need for effective treatments.

NV-387 is a broad-spectrum antiviral that has shown efficacy against several viruses, including measles, in animal models. There is currently no approved treatment for measles, underscoring the potential impact of NV-387 in mitigating the disease's health impacts globally.